Osiris hits milestone with stem cell trial

Osiris Therapeutics has hit a notable milestone, completing enrollment for a late-stage stem cell trial. Researchers will explore the benefits of Prochymal for steroid-refractory acute Graft versus Host Disease, a complication of bone marrow transplantation. "Completion of this study's enrollment represents an outstanding accomplishment for the transplantation field," said Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center, professor at the University of Washington and lead investigator for the trial. "Steroid-refractory acute Graft versus Host disease poses one of the most serious and difficult-to-treat complications that can occur after bone marrow transplantation. Previous studies have not identified reliably effective treatments, and no drugs have been approved for this devastating disease."

- read the press release

Related Articles:
Osiris shares soar on $1.38B Genzyme pact
Osiris inks $224M contract
Osiris shares jump on therapy results (Nov 2007)
Upstart biotech attracts A-list investors (Oct 2007)